Menu ×


Polycystic Kidney Disease Drugs Market Analysis byType {Autosomal Dominant Polycystic Kidney Disease (ADPKD),Autosomal Recessive Polycystic Kidney Disease (ARPKD), and Others}, by Treatment (Medication, Surgery, and Others), by Diagnosis (Ultrasound, CT scan, and MRI Scan), and by End User (Hospitals, Specialty Clinics, and Others)– Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • July 13, 2022- Pharmacokinetics Bridging Study Part 1 of XORTX Therapeutics Inc. XRX-OXY-101 (“PK Clinical Trial”) showed an increase in oral bioavailability for two versions compared to a control formulation in advance of ADPKD's late-stage phase 3 registration trial.
  • April 25, 2022: Pano Therapeutics, Inc announced that it has acquired the privately-held NovaTarg Therapeutics, Inc. to strengthen Pano Therapeutic Inc’s drug discovery and development capabilities and enhance its portfolio. 

Global Polycystic Kidney Disease Drugs Market Size, Forecast, and Trend Highlights Over 2022 - 2033

Base Year


Forecast Year




Base Year Market Size (2021)

~USD 451 Million

Forecast Year Market Size (2031)

~USD 732 Million

The global polycystic kidney disease drugs market is estimated to garner a revenue of USD 732 Million by the end of 2033 by growing at a CAGR of ~7% over the forecast period, i.e., 2023 – 2033. Further, the market generated revenue of USD 451 Million in the year 2023. The growth of the market can be attributed primarily to the increasing incidence of chronic kidney diseases worldwide. It was observed that CKD prevalence among the global population is estimated at 14%.In accordance with the centers for disease control and prevention, a total of 37 million Americans are estimated to have chronic kidney disease, that is 15% of the region's population.


Get more information on this report: Request Sample PDF

A genetic disease known as polycystic kidney disease (PKD) results in excessive growth of cysts in the kidney and consequently results in kidney failure. Cysts fill the kidneys with fluid, causing them to become enlarged and inhibiting their ability to filter waste products out of the blood. As a result of PKD, chronic kidney disease can also lead to end-stage renal diseases.Furthermore, the advancement in technology, growing awareness about kidney diseases, rise in PKD drug trials, growth in approval drugs by government along with development of a wide range of medications by key players are anticipated to expand global polycystic kidney disease drugs market size during the forecast period. For instance, Reata Pharmaceuticals, Inc. announced positive phase II results for bardoxolone methyl in chronic renal disease caused by the alport syndrome and autosomal dominant polycystic kidney disease in July 2018. 

Global Polycystic Kidney Disease Drugs Market: Growth Drivers and Challenges

Growth Drivers

  • Surge In Incidence Of Autosomal Dominant Polycystic Kidney Diseases (ADPKD)- For instance, around 200,000 to 500,000 people in the United States and another 13,000,000 people around the world suffer from ADPKD, and only about 25% of the population are aware of the disease

ADPKD is a rare condition, but it contributes significantly to chronic kidney disease and kidney failure. In addition, polycystic kidney disease, the most common chronic kidney disease, substantially increases the prevalence of chronic kidney disease. As a result, an increasing prevalence of ADPKD is expected to drive global polycystic kidney disease drugs market growth over the forecast period.

  • Growing Initiatives To Raise Awareness About PKDs- For instance, PKD Foundation is the only non-profit in the U.S. exclusively dedicated to treating and curing polycystic kidney disease. Over 1,300 research studies were funded and USD 1.5 billion in research funding has been leveraged. 
  • Increasing Healthcare Spending Worldwide - According to the Centers for Medicare & Medicaid Services, the United States spent USD 4.1 trillion on healthcare services in 2020, representing 19.7% of the GDP. 
  • Rising Number of Research and Development Activities-According to the World Bank, the number of researchers in R&D activities has increased from 14,12 researchers per million in 2015 to 1,597 researchers per million in 2018.  
  • Growth In Personal Disposable Income- According to the Bureau of Economic Analysis, personal income increased by USD 47.0 billion (0.2%) in July 2020, and disposable personal income (DPI) increased by USD 37.6 billion (0.2%).


  • Insufficient Number Of Approved Drugs
  • Strict Government Guidelines For Drug Trials 
  • High Expenses Associated With Treatment

The global polycystic kidney disease drugs market is segmented and analyzed for demand and supply by type into autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and others. Among these segments, the autosomal dominant polycystic kidney disease segment is anticipated to capture the largest market size in the global polycystic kidney disease drugs market owing to the increasing incidence of autosomal dominant polycystic kidney diseases worldwide. It was observed that, the prevalence of ADPKD is estimated to be somewhere between 1 in 500-1,000 among the general population. Each year, about 5,900 new cases are recorded in the United States. 

Major Macro-Economic Indicators Impacting the Market Growth


The chemical industry is a major component of the economy. According to the U.S. Bureau of Economic Analysis, in 2020, for the U.S., the value added by chemical products as a percentage of GDP was around 1.9%. Additionally, according to the World Bank, Chemical industry in the U.S. accounted for 16.43% to manufacturing value-added in 2018. With the growing demand from end-users, the market for chemical products is expected to grow in future. According to UNEP (United Nations Environment Program), the sales of chemicals are projected to almost double from 2017 to 2030. In the current scenario, Asia Pacific is the largest chemical producing and consuming region. China has the world’s largest chemical industry, that accounted for annual sales of approximately more than USD 1.5 trillion, or about more than one-third of global sales, in recent years. Additionally, a vast consumer base and favorable government policies have boosted investment in China’s chemical industry. Easy availability of low-cost raw material & labor as well as government subsidies and relaxed environmental norms have served as a production base for key vendors globally. On the other hand, according to the FICCI (Federation of Indian Chambers of Commerce & Industry), the chemical industry in India was valued at 163 billion in 2019 and it contributed 3.4% to the global chemical industry. It ranks 6th in global chemical production. This statistic shows the lucrative opportunity for the investment in businesses in Asia Pacific countries in the upcoming years.

Global Polycystic Kidney Disease Drugs Market Regional Synopsis

Regionally, the global polycystic kidney disease drugs market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033 backed by the rise in per capita income along with rising awareness of the early diagnosis of chronic kidney diseases in the region. In accordance with data provided by the World Bank, the annual income of each individual in the United States rose by USD 69287.5 in 2021 from USD 63027.7 in year 2020. Moreover, affordable health care policies, intensive drug research and development, significant increase in medical and health care industries, and drug accessibility are further expected to fuel the polycystic kidney disease drugs market in the region during the forecast period.


The global polycystic kidney disease drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global polycystic kidney disease drugs market includes the following segments:

By Type

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Autosomal Recessive Polycystic Kidney Disease (ARPKD)
  • Others

By Treatment

  • Medication
  • Surgery
  • Others

By Diagnosis

  • Ultrasound
  • CT Scan
  • MRI Scan

By End User

  • Hospitals
  • Specialty Clinics
  • Others

Top Featured Companies Dominating the Global Polycystic Kidney Disease Drugs Market

  • Otsuka Pharmaceutical Co., Ltd.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Exelixis, Inc.
  • Celgene Corp
  • XORTX Pharma Corp.
  • ManRos Therapeutics
  • Palladio Biosciences
  • Regulus Therapeutics, Inc.
  • Kadmon Holdings, Inc.
  • Reata Pharmaceuticals, Inc.
  • PanoTherapeutics,Inc.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved